Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Purdue Pharma LP |
---|---|
Information provided by: | Purdue Pharma LP |
ClinicalTrials.gov Identifier: | NCT00315887 |
The objective of this study is to assess the safety and efficacy of the buprenorphine transdermal system (5, 10, and 20 mg) in comparison to placebo transdermal system and hydrocodone/acetaminophen in subjects with chronic back pain. The double-blind treatment intervention duration is 56 days during which time supplemental analgesic medication (ibuprofen) will be provided to all subjects in addition to study drug.
Condition | Intervention | Phase |
---|---|---|
Chronic Low Back Pain |
Drug: Buprenorphine transdermal delivery system |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | A Double-Blind Comparative Study of Buprenorphine Transdermal System (BTDS) and Hydrocodone/Acetaminophen Tablets in Patients With Chronic Back Pain |
Estimated Enrollment: | 250 |
Study Start Date: | April 1999 |
Estimated Study Completion Date: | October 1999 |
Buprenorphine is a synthetic opioid analgesic with over twenty-five years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain. Transdermal systems may offer advantages over currently indicated oral products including ease and convenience of use, improved compliance, possible reduction in patient care, and prolonged and consistent delivery of drug.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-specific exclusion/inclusion criteria may apply.
Study ID Numbers: | BP98-1201 |
Study First Received: | April 18, 2006 |
Last Updated: | May 1, 2006 |
ClinicalTrials.gov Identifier: | NCT00315887 |
Health Authority: | United States: Food and Drug Administration |
low back pain opioid transdermal |
Signs and Symptoms Buprenorphine Hydrocodone Neurologic Manifestations |
Low Back Pain Pain Back Pain Acetaminophen |
Sensory System Agents Therapeutic Uses Narcotic Antagonists Physiological Effects of Drugs Nervous System Diseases Central Nervous System Depressants |
Narcotics Peripheral Nervous System Agents Analgesics Central Nervous System Agents Pharmacologic Actions Analgesics, Opioid |